|
No product was provided for analysis.Device remains implanted.There was no adverse event with the patient reported.The device history records were reviewed to confirm that the device passed all applicable in-process and final inspections.No product was returned to oscor inc.For evaluation; however, a complaint notification was provided.Without the return of the actual device in question for evaluation, oscor inc.Is unable to determine the exact cause for this incident.At this time, it is not possible to assign a definitive root cause for the event as reported.The complaint is non-verifiable as the product was not returned for evaluation.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|
|
The customer reported that the right atrial (ra) lead with a lead extension was exhibiting high thresholds.It was also reported that the right ventricular (rv) lead with a lead extension exhibited high thresholds, high impedance and an impedance spike.Both leads remain in use.No patient complications have been reported as a result of this event.No injury no harm to the patient.Both leads with lead extensions remain in use, no intervention completed.No intervention completed.Implant date (b)(6) 2024, remains in use.
|